

Lessons from SARS: control of acute lung failure by the SARS receptor ACE2

Keiji Kuba · Yumiko Imai · Shuan Rao ·
Chengyu Jiang · Josef M. Penninger

Received: 16 February 2006 / Accepted: 13 June 2006 / Published online: 19 September 2006
© Springer-Verlag 2006

Abstract Angiotensin-converting enzyme 2 (ACE2), a second angiotensin-converting enzyme (ACE), regulates the renin–angiotensin system by counterbalancing ACE activity. Accumulating evidence in recent years has demonstrated a physiological and pathological role of ACE2 in the cardiovascular systems. Recently, it has been shown that severe acute respiratory syndrome (SARS) coronavirus, the cause of SARS, utilizes ACE2 as an essential receptor for cell fusion and *in vivo* infections in mice. Intriguingly, ACE2 acts as a protective factor in various experimental models of acute lung failure and, therefore, acts not only as a key determinant for SARS virus entry into cells but also contributes to SARS pathogenesis. Here we review the role of ACE2 in disease pathogenesis, including lung diseases and cardiovascular diseases.

Keywords Angiotensin-converting enzyme 2 · Renin–angiotensin system · Severe acute respiratory syndrome · SARS coronavirus · Acute respiratory distress syndrome · Knockout mice

K. Kuba (✉) · Y. Imai · J. M. Penninger
IMBA, Institute of Molecular Biotechnology
of the Austrian Academy of Sciences,
Dr. Bohr-gasse 3,
1030 Vienna, Austria
e-mail: Keiji.kuba@imba.oeaw.ac.at

J. M. Penninger
e-mail: Josef.penninger@imba.oeaw.ac.at

S. Rao · C. Jiang
Institute of Basic Medical Sciences, Chinese Academy of Medical
Sciences & Peking Union Medical College,
5 Dongdan Santiao,
Beijing 100005, China



KEIJI KUBA
received his M.D. degree from Kyushu University, Fukuoka, Japan, and his Ph.D. degree from the Department of Surgery, Graduate School of Medicine, Kyushu University, Japan. He is presently a postdoctoral research fellow at the Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria. His research interests include pulmonary and cardiovascular diseases and those relevant animal models with genetically modified animals.



JOSEF MARTIN PENNINGER
received his M.D. degree from the University of Innsbruck, Medical School, Austria. He is presently a full professor in the University of Vienna, Vienna, Austria, and is the scientific and administrative director of the Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria. His research focuses on the generation of genetically modified mice and animal models of human diseases, including cancer, cardiovascular disease, autoimmunity, and bone disease.

Introduction

The renin–angiotensin system (RAS) plays a central role in the control of cardiovascular functions by maintaining the

physiologic homeostasis of blood pressure and electrolyte balance. Abnormal activation of the RAS has been associated with the pathophysiology of cardiovascular diseases such as hypertension, myocardial infarction, or heart failure [1–3]. For many years, the angiotensin-converting enzyme (ACE) has been known as the key enzyme in the regulation of the RAS [4, 5].

In the year 2000, a novel homologue of ACE was cloned, termed angiotensin-converting enzyme 2 (ACE2) [6, 7]. Despite the sequence similarity in their metalloprotease catalytic domains, ACE and ACE2 differ in their substrate specificity. This difference has important physiological consequences. Whereas ACE cleaves the decapeptide angiotensin I (ANG I) into an octapeptide angiotensin II (ANG II) [4, 5], ACE2 functions as a carboxypeptidase, cleaving a single residue from ANG I, generating angiotensin-(1–9) [6, 7], and a single residue from ANG II to generate angiotensin-(1–7) [7–9] (Fig. 1). Targeted disruption of murine ACE2 resulted in increased systemic ANG II levels, impaired cardiac contractility in aged mice, and upregulation of hypoxia-induced genes in the heart [10]. These genetic data for the first time demonstrated that ACE2 functions as a negative regulator of ANG II levels within the RAS in the heart.

Recently, ACE2 has been identified as a functional receptor for the severe acute respiratory syndrome (SARS)-

coronavirus (SARS-CoV) in vitro [11, 12] and in vivo [13]. During several months in 2003, a newly identified illness, termed SARS, spread rapidly throughout the world, causing more than 800 deaths and disrupting travel, economics, and social life [14–16]. A novel coronavirus, termed SARS-CoV, was identified as the causative SARS pathogen [17, 18]. The death rate following infection was ~10% due to the development of atypical pneumonia characterized by high fever and the development of acute respiratory distress syndrome (ARDS) [19–21]. ARDS is the most severe form of acute lung injury, characterized by pulmonary edema, accumulation of inflammatory cells, and severe hypoxia [19–21]. ARDS has a very high mortality rate of 30–50% and affects nearly one million individuals worldwide/year. ARDS can be triggered by various diseases such as sepsis, trauma, aspiration, acute pancreatitis, or pneumonias including infections with SARS-CoV or avian and human influenza viruses [19, 20, 22, 23].

The SARS-CoV receptor ACE2 is expressed in the lungs of healthy and diseased humans [24], and our recent studies definitely showed that ACE2 is indeed an essential receptor for SARS infections in mice in vivo [13]. In the pathogenesis of ARDS, ANG II is upregulated by ACE and drives severe lung failure via the ANG II type 1 (AT1) receptor [25]. On the other hand, ACE2 and the ANG II type 2 receptor regulate opposing effects and have protective roles against lung injury. In addition, SARS-CoV-mediated down-regulation of ACE2 appears to play a causative role in severe acute lung injury in SARS through enhanced activation of AT1 receptors [13].




Fig. 1 Current view of ACE and ACE2 functions. ANG I (DRVYIHPFHL) serves as a substrate for both ACE and ACE2. ANG II (DRVYIHPF) is known to act as vasoconstrictor in vivo. The function of angiotensin 1–9 (DRVYIHPFH) is not well understood. Both ACE and ACE2 are involved in the production of the vasodilator peptide angiotensin 1–7 (DRVYIHPF). Red arrowheads ACE cleavage site; blue arrowheads ACE2 cleavage sites. It should be noted that ACE2 is an unspecific protease and can cleave multiple additional substrates, such as apelin

ACE2 in cardiovascular diseases

The beneficial effects of ACE inhibitors or AT1 receptor blockers on hypertension in the clinics have been functionally proven by in vivo models using mice deficient in ACE, angiotensinogen, or the ANG II type 1a receptor, all of which mice show lower blood pressure [9, 26, 27] (Fig. 1). The in vitro activity of ACE2 to cleave ANG II to angiotensin-(1–7) encouraged researchers to propose that ACE2 is also a major regulator of blood pressure homeostasis. After our initial study showing reduced ACE2 expression in different hypertensive rat strains [10], the upregulation of ACE2 expression is reported in the under-nutrition programmed hypertension rats [28] and AT1 receptor blocker-treated [29] or all-trans retinoic acid-treated [30] hypertensive rats, accompanied by a reduction in blood pressure. On the other hand, it was surprising to find that *ace2* knockout mice per se show apparently normal blood pressures [10]. However, it is likely that mouse-strain-specific background genes might influence the effects of ACE2 on blood pressure. Despite

no direct correlation between essential hypertension and *ACE2* polymorphisms in an earlier clinical study [31], two recent Chinese population studies indicated that the *ACE2* G8790A polymorphism is associated with cardiac incompetence in essential hypertension patients or with hypertension in metabolic syndrome patients [32, 33]. These findings implicated the significance of the *ACE2* G8790A polymorphism in cardiovascular diseases. Of note, all of these studies investigated single nucleotide polymorphisms (SNPs) located in the introns of the *ACE2* gene; the effects of these SNPs on the activity and/or expression of ACE2 are still unknown. Nevertheless, the data of hypertensive rats and human ACE2 SNPs implicate the possible significance of ACE2 in blood pressure regulation, and further studies are awaited.

Initially, ACE2 was identified and cloned from human failing heart tissue [7]. In line with this, increased ACE2 expression in the failing heart has been reported independently [34–37], and the protective role of ACE2 in pressure-overload-induced heart failure was recently shown in a transverse aortic constriction model using *ace2* knockout mice [38]. Furthermore, the function of ACE2 in basal condition was defined by the echocardiography measurements showing a progressive impairment of heart contractility in aged *ace2*-gene-deficient mice without histological changes in the heart [10]. The observed phenotype of *ace2* mutant mice resembles the defective heart found in patients with cardiac stunning/hibernation [39]. Cardiac stunning and hibernation reflect adaptive responses to prolonged states of tissue hypoxia that can occur in coronary artery disease or following bypass surgery [39, 40]. Pathologically, chronic hypoxic conditions can lead to compensatory changes in myocyte metabolism [41], upregulation of hypoxia-induced genes [42, 43], and possibly resembling myocyte-specific vascular endothelial growth factor mutant mice [44]. The link between cardiac stunning/hibernation and the heart defect observed in *ace2* knockout mice has to be further investigated.

Interestingly, additional deletion of *ace* gene on an *ace2* mutant background rescued the cardiac contractility phenotype of *ace2* single knockout mice and also reversed the increased ANG II peptide levels [10]. The normal cardiac functions of *ace/ace2* double-mutant mice suggest that ACE's catalytic products account, at least in part, for the observed contractile impairment of old *ace2* single-mutant mice [10]. These observations for the first time demonstrated, at the genetic level, that ACE2 counterbalances the enzymatic actions of ACE. It seems that increased local cardiac ANG II might have been the cause for the cardiac abnormalities in *ace2*-deficient mice. Nevertheless, it remains unclear why the elevated heart ANG II levels do not induce cardiac hypertrophy in the *ace2*-deficient mice. For instance, in experimental models, it is well established

that cardiomyocytes express ANG II receptors and undergo hypertrophy and fibrosis in response to ANG II stimulation [45]. Thus, it is important to note that ANG II-independent pathways could also play an important role in ACE/ACE2-regulated heart functions.

ACE2 in lung diseases

The major sites of ACE expression in our body are vascular endothelial cells in the lungs, and thus, it has been proposed that systemic ANG II is mainly generated in the lung [4, 5, 46]. Experimentally, a possible role of ANG II in lung disease has been implied from animal models of pulmonary fibrosis elicited by bleomycin or irradiation-mediated lung injury. In bleomycin-induced pulmonary fibrosis in rats or mice, ACE inhibitors or AT1 receptor blockers can attenuate epithelial apoptosis, interstitial fibrosis, and collagen deposition [47–50]. Those reports implicated ACE inhibitors or AT1 receptor blockers as possible therapy for pulmonary fibrosis seen in idiopathic pulmonary fibrosis [51], sarcoidosis [52], irradiation-induced pneumonitis [47], or fibrosis that develops as a side effect of chemotherapy in cancer patients [53]. However, there are not enough published clinical studies to make any firm conclusion whether these inhibitors indeed show beneficial effects. A recent cohort study of ARDS showed the significant association between ACE insertion/deletion (D) polymorphism and the susceptibility and outcome of ARDS [54]. The D allele of the human *ACE* gene confers increased ACE activity in plasma, and the DD genotype frequency was increased in the patients with ARDS compared with the control groups [54]. Moreover, the DD allele was significantly associated with mortality in the ARDS group. Thus, based on inhibitor experiments in rodents and *ACE* allelic correlation studies in humans, it has been suggested that the RAS could have a role in acute lung failure and pulmonary fibrosis.

Our group investigated the role of ACE2 in ARDS by using *ace2* knockout mice. In three different ARDS models, acid-aspiration-induced ARDS, endotoxin-induced ARDS, and peritoneal sepsis-induced ARDS, *ace2* knockout mice show very severe disease compared with wild-type mice [25]. Loss of ACE2 expression in mutant mice resulted in enhanced vascular permeability, increased lung edema, neutrophil accumulation, and worsened lung function. Importantly, treatment with catalytically active recombinant ACE2 protein improved the symptoms of acute lung injury in wild-type mice, as well as in *ace2* knockout mice [25]. Thus, ACE2 plays a protective role in acute lung injury. Mechanistically, the negative regulation of ANG II levels by ACE2 accounts, in part, for the protective function of ACE2 in ARDS. For example, AT1 inhibitor treatment or

additional *ace* gene deficiency on an *ace2* knockout background rescues the severe phenotype of *ace2* single-mutant mice in acute lung injury [25]. In addition, *ace* knockout mice and *at1a receptor* knockout mice showed improved symptoms of acute lung injury [25]. Therefore, in acute lung injury, ACE, ANG II, and AT1 receptor function as lung-injury-promoting factors, while ACE2 protects from lung injury [25]. However, similar to the heart, we also have evidence that ACE2-regulated, but ANG II-independent, pathways [8, 55] might play a critical role in controlling ARDS following acute lung injury (Fig. 2).

ACE2 in SARS pathology

Within months of publication of the SARS-CoV genome [56, 57], ACE2 was identified as a potential receptor using in vitro cell line studies [11]. ACE2 has been demonstrated to bind SARS-CoV spike and to support “syncytia formation,” the fusion of spike-protein-expressing cells into large multinucleated cells that can also be seen in “real” SARS infections [11]. After the identification of ACE2 as a SARS receptor in vitro, liver-specific ICAM3-grabbing nonintegrin (L-SIGN) (also known as CD209L) was

reported as a second receptor for SARS-CoV infection [58] (Fig. 2). Certainly, both receptors seem functional for in vitro viral entry, but it was unclear whether those receptors are required for in vivo SARS infections.

Using a SARS infection model in *ace2* knockout mice, our group was able to show that ACE2 is indeed essential for SARS infections in vivo [13]. When *ace2* knockout mice are infected with SARS-CoV, they were resistant to virus infection [13]. No lung histology from *ace2* knockout mice challenged with SARS-CoV showed signs of inflammation [13], whereas some (but not all) SARS-infected wild-type mice displayed mild inflammation with leukocyte infiltration [13, 59, 60]. Thus, ACE2 is an essential receptor for SARS infections in vivo. Moreover, the importance of L-SIGN in SARS infection has been recently highlighted by the genetic analyses of a polymorphism that determines different numbers (3–9) of tandem repeat domains in exon 4 of the human L-SIGN protein [61]. Individuals homozygous for these tandem repeats (i.e., the same number of tandem repeats in both alleles) are less susceptible to SARS infections than ones heterozygous for the repeats (i.e., the different number of tandem repeats in each allele) [62]. It would be interesting to further investigate the functional importance of L-SIGN in vivo SARS infections using




Fig. 2 Schematic diagram of the role of the RAS in acute lung failure and proposed SARS-CoV action. In acute lung injury, such as acid aspiration, pneumonia, or sepsis, the generation of ANG II from ANG I is enhanced by ACE, and ANG II induces acute lung failure through stimulation of the AT1 receptor, while ACE2 and ANG II type 2

receptor negatively regulate this pathway and protect from acute lung failure. On the other hand, SARS-CoV infection is mediated through binding of the SARS-Spike protein to ACE2 or L-SIGN and downregulates the protective molecule ACE2, and thus leads to severe lung injury and acute lung failure

model systems such as L-SIGN transgenic mice, and to genetically compare the role of L-SIGN to that of ACE2 in *ace2*-gene-deficient mice.

One mystery of SARS-CoV is why, in contrast to the other coronaviruses infecting humans, infections with the SARS-CoV trigger severe lung disease with such high mortality. Accumulating evidence further indicates that severe SARS infections are dependent on the burden of viral replication, as well as on the immunopathologic consequences of the host response in SARS pathogenesis (see reviews [63, 64]). Moreover, our own studies have implicated the involvement of the RAS in SARS pathogenesis: first, ACE2 is a critical SARS receptor in vivo and, second, ACE2 and other components of the RAS play a central role in controlling the severity of acute lung failure once the disease process has started [13]. Intriguingly, before the identification of ACE2 as a SARS receptor, it has been reported that some SARS patients develop impaired heart contractility using echocardiographic measurements [65]. Certainly, the observed decrease in left ventricular performance during the acute infection phase may be related to a systemic inflammatory condition [66], which is not unique to SARS. Nevertheless, it is interesting to contemplate a possible link of the impaired heart function of SARS patients and the reduced heart contractility in *ace2* mutant mice. In line with this idea, wild-type mice infected with SARS-CoV showed markedly down-regulated ACE2 expression in lungs [13], as well as in hearts (unpublished). Moreover, treatment with recombinant SARS-Spike protein, without any other virus components, down-regulates ACE2 expression in vitro and in vivo [13]. Thus, Spike-treated wild-type mice resemble *ace2* knockout mice, and, similar to *ace2* mutant mice, Spike-treated wild-type mice show enhanced RAS signaling, leading to markedly more severe pathology in acute lung injury. Therefore, the down-regulation of ACE2 expression by Spike in SARS-CoV infections might be a possible explanation for SARS pathogenesis, especially in disease progression to ARDS. Although the enhanced RAS signaling is unique in SARS-CoV infection, the down-regulation of virus receptor by interaction with virus ligand is also seen in other viruses. For instance, CD4, a receptor for HIV, internalizes with HIV gp120, resulting in the disruption of immune cell functions [67], and CD46, a measles receptor, is down-regulated by measles hemagglutinin, leading to the impairment of complement pathways and immune systems [68]. On the other hand, any consequences of the down-regulation of sialo-glycoconjugate receptor by influenza A virus [69] are yet unknown. The finding of enhanced RAS signaling and severe acute lung injury as consequences of ACE2 down-regulation by SARS-CoV might possibly implicate that other emerging infectious lung diseases, like H5N1 avian flu, may also

utilize the receptor down-regulation system to impair host immune/inflammatory systems and induce severe lung diseases. Thus, it is interesting to investigate the consequences of down-regulation of other virus receptors upon virus infection.

Concluding remarks

ACE2 has now been identified as a key factor for protection from ARDS/acute lung injury, and ACE2 functions as a critical SARS receptor in vivo. Since SARS Spike-protein-mediated ACE2 down-regulation appears to contribute to the severity of lung failure, these findings may explain how the SARS-CoV has turned into a lethal virus. In addition, in an acid aspiration ARDS mouse model, strong down-regulation of ACE2 protein in the injured lung was observed, while ACE expression remained unchanged. Thus, recombinant ACE2 protein could not only be a treatment to block the spreading of SARS but also to protect SARS patients from developing lung failure. Furthermore, those findings could apply to investigating the therapeutic efficacy of ACE2 in ARDS that develops in other emerging lung infectious diseases, like avian influenza A (H5N1) [70] or other diseases that affect lung function [71]. In addition to recombinant ACE2 protein therapy, ACE2 gene therapy would be another candidate. Recently, lentivirus-mediated gene delivery of ACE2 into rat hearts was shown to successfully attenuate ANG II-induced cardiac hypertrophy [72]. However, especially for the acute phase of ARDS, tissue-specific delivery of exogenous recombinant ACE2 protein might be the first line of choice while avoiding systemic adverse effects. We look forward to the further elucidation of the pathophysiological role of ACE2 and to the use of ACE2 as a therapeutic target.

Acknowledgements We thank M.J. Crackower, R. Sarao, and many others for their contributions. Supported by grants from The National Bank of Austria, The Austrian Ministry of Science and Education, IMBA, and EUGeneHeart to JMP. K.K. is supported by a Marie Curie Fellowship from the EU.

References

1. Ferrario CM (1990) The renin-angiotensin system: importance in physiology and pathology. *J Cardiovasc Pharmacol* 15(Suppl 3): S1–S5
2. Inagami T, Yamano Y, Bardhan S et al (1995) Cloning, expression and regulation of angiotensin II receptors. *Adv Exp Med Biol* 377:311–317
3. Nicholls MG, Richards AM, Agarwal M (1998) The importance of the renin-angiotensin system in cardiovascular disease. *J Hum Hypertens* 12(5):295–299

4. Skeggs LT, Dorer FE, Levine M, Lentz KE, Kahn JR (1980) The biochemistry of the renin–angiotensin system. *Adv Exp Med Biol* 130:1–27
5. Turner AJ, Hooper NM (2002) The angiotensin-converting enzyme gene family: genomics and pharmacology. *Trends Pharmacol Sci* 23(4):177–183
6. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ (2000) A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. *J Biol Chem* 275(43):33238–33243
7. Donoghue M, Hsieh F, Baronas E et al (2000) A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. *Circ Res* 87(5):E1–E9
8. Vickers C, Hales P, Kaushik V et al (2002) Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. *J Biol Chem* 277(17):14838–14843
9. Kregel JH, John SW, Langenbach LL et al (1995) Male–female differences in fertility and blood pressure in ACE-deficient mice. *Nature* 375(6527):146–148
10. Crackower MA, Sarao R, Oudit GY et al (2002) Angiotensin-converting enzyme 2 is an essential regulator of heart function. *Nature* 417(6891):822–828
11. Li W, Moore MJ, Vasilieva N et al (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature* 426(6965):450–454
12. Wang P, Chen J, Zheng A et al (2004) Expression cloning of functional receptor used by SARS coronavirus. *Biochem Biophys Res Commun* 315(2):439–444
13. Kuba K, Imai Y, Rao S et al (2005) A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. *Nat Med* 11(8):875–879
14. Tsang KW, Ho PL, Ooi GC et al (2003) A cluster of cases of severe acute respiratory syndrome in Hong Kong. *N Engl J Med* 348(20):1977–1985
15. Lee N, Hui D, Wu A et al (2003) A major outbreak of severe acute respiratory syndrome in Hong Kong. *N Engl J Med* 348(20):1986–1994
16. Poutanen SM, Low DE, Henry B et al (2003) Identification of severe acute respiratory syndrome in Canada. *N Engl J Med* 348(20):1995–2005
17. Ksiazek TG, Erdman D, Goldsmith CS et al (2003) A novel coronavirus associated with severe acute respiratory syndrome. *N Engl J Med* 348(20):1953–1966
18. Drosten C, Gunther S, Preiser W et al (2003) Identification of a novel coronavirus in patients with severe acute respiratory syndrome. *N Engl J Med* 348(20):1967–1976
19. Hudson LD, Milberg JA, Anardi D, Maunder RJ (1995) Clinical risks for development of the acute respiratory distress syndrome. *Am J Respir Crit Care Med* 151(2 Pt 1):293–301
20. Ware LB, Matthay MA (2000) The acute respiratory distress syndrome. *N Engl J Med* 342(18):1334–1349
21. Vincent JL, Sakr Y, Ranieri VM (2003) Epidemiology and outcome of acute respiratory failure in intensive care unit patients. *Crit Care Med* 31(Suppl 4):S296–S299
22. Andrews P, Azoulay E, Antonelli M et al (2005) Year in review in intensive care medicine, 2004. I Respiratory failure, infection, and sepsis. *Intensive Care Med* 31(1):28–40
23. Fouchier RA, Schneeberger PM, Rozendaal FW et al (2004) Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. *Proc Natl Acad Sci U S A* 101(5):1356–1361
24. Hamming I, Timens W, Bulthuis ML, Lely AT, Navis GJ, van Goor H (2004) Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol* 203(2):631–637
25. Imai Y, Kuba K, Rao S et al (2005) Angiotensin-converting enzyme 2 protects from severe acute lung failure. *Nature* 436(7047):112–116
26. Tanimoto K, Sugiyama F, Goto Y et al (1994) Angiotensinogen-deficient mice with hypotension. *J Biol Chem* 269(50):31334–31337
27. Sugaya T, Nishimatsu S, Tanimoto K et al (1995) Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. *J Biol Chem* 270(32):18719–18722
28. Riviere G, Michaud A, Breton C et al (2005) Angiotensin-converting enzyme 2 (ACE2) and ACE activities display tissue-specific sensitivity to undernutrition-programmed hypertension in the adult rat. *Hypertension* 46(5):1169–1174
29. Igase M, Strawn WB, Gallagher PE, Geary RL, Ferrario CM (2005) Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1–7) expression in the aorta of spontaneously hypertensive rats. *Am J Physiol Heart Circ Physiol* 289(3):H1013–H1019
30. Zhong JC, Huang DY, Yang YM et al (2004) Upregulation of angiotensin-converting enzyme 2 by All-trans retinoic acid in spontaneously hypertensive rats. *Hypertension* 44(1):11–16
31. Benjafield AV, Wang WY, Morris BJ (2004) No association of angiotensin-converting enzyme 2 gene (ACE2) polymorphisms with essential hypertension. *Am J Hypertens* 17(7):624–628
32. Liu TB, Shang HP, Zhang KX et al (2005) Association of angiotensin I converting enzyme 2 gene polymorphism with essential hypertension in Chinese. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi* 22(5):569–571
33. Zhong J, Yan Z, Liu D et al (2006) Association of angiotensin-converting enzyme 2 gene A/G polymorphism and elevated blood pressure in Chinese patients with metabolic syndrome. *J Lab Clin Med* 147(2):91–95
34. Zisman LS, Keller RS, Weaver B et al (2003) Increased angiotensin-(1–7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme homologue ACE2. *Circulation* 108(14):1707–1712
35. Goulter AB, Goddard MJ, Allen JC, Clark KL (2004) ACE2 gene expression is up-regulated in the human failing heart. *BMC Med* 2(1):19
36. Burrell LM, Risvanis J, Kubota E et al (2005) Myocardial infarction increases ACE2 expression in rat and humans. *Eur Heart J* 26(4):369–375 (discussion 322–364)
37. Kittleson MM, Minhas KM, Irizarry RA et al (2005) Gene expression analysis of ischemic and nonischemic cardiomyopathy: shared and distinct genes in the development of heart failure. *Physiol Genomics* 21(3):299–307
38. Yamamoto K, Ohishi M, Katsuya T et al (2006) Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. *Hypertension* 47(4):718–726
39. Heusch G (1998) Hibernating myocardium. *Physiol Rev* 78(4):1055–1085
40. Kloner RA, Jennings RB (2001) Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part I. *Circulation* 104(24):2981–2989
41. Murphy AM, Kogler H, Georgakopoulos D et al (2000) Transgenic mouse model of stunned myocardium. *Science* 287(5452):488–491
42. Kietzmann T, Roth U, Jungermann K (1999) Induction of the plasminogen activator inhibitor-1 gene expression by mild hypoxia via a hypoxia response element binding the hypoxia-inducible factor-1 in rat hepatocytes. *Blood* 94(12):4177–4185
43. Guo K, Searfoss G, Krolikowski D et al (2001) Hypoxia induces the expression of the pro-apoptotic gene BNIP3. *Cell Death Differ* 8(4):367–376
44. Giordano FJ, Gerber HP, Williams SP et al (2001) A cardiac myocyte vascular endothelial growth factor paracrine pathway is

- required to maintain cardiac function. *Proc Natl Acad Sci USA* 98 (10):5780–5785
45. van Kats JP, Methot D, Paradis P, Silversides DW, Reudelhuber TL (2001) Use of a biological peptide pump to study chronic peptide hormone action in transgenic mice. Direct and indirect effects of angiotensin II on the heart. *J Biol Chem* 276(47):44012–44017
 46. Boehm M, Nabel EG (2002) Angiotensin-converting enzyme 2—a new cardiac regulator. *N Engl J Med* 347(22):1795–1797
 47. Ward WF, Sharplin J, Franko AJ, Hinz JM (1989) Radiation-induced pulmonary endothelial dysfunction and hydroxyproline accumulation in four strains of mice. *Radiat Res* 120(1):113–120
 48. Wang R, Ibarra-Sunga O, Verlinski L, Pick R, Uhal BD (2000) Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by captopril or by a caspase inhibitor. *Am J Physiol Lung Cell Mol Physiol* 279(1):L143–L151
 49. Li X, Rayford H, Uhal BD (2003) Essential roles for angiotensin receptor AT1a in bleomycin-induced apoptosis and lung fibrosis in mice. *Am J Pathol* 163(6):2523–2530
 50. Otsuka M, Takahashi H, Shiratori M, Chiba H, Abe S (2004) Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist. *Thorax* 59 (1):31–38
 51. Thannickal VJ, Flaherty KR, Martinez FJ, Lynch JP 3rd (2004) Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy. *Expert Opin Pharmacother* 5(8):1671–1686
 52. McGrath DS, Foley PJ, Petrek M et al (2001) Ace gene I/D polymorphism and sarcoidosis pulmonary disease severity. *Am J Respir Crit Care Med* 164(2):197–201
 53. Newman RA, Kimberly PJ, Stewart JA, Kelley J (1980) Assessment of bleomycin lung toxicity using angiotensin-converting enzyme in pulmonary lavage. *Cancer Res* 40(10):3621–3626
 54. Marshall RP, Webb S, Bellingan GJ et al (2002) Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. *Am J Respir Crit Care Med* 166(5):646–650
 55. Danilczyk U, Eriksson U, Oudit GY, Penninger JM (2004) Physiological roles of angiotensin-converting enzyme 2. *Cell Mol Life Sci* 61(21):2714–2719
 56. Rota PA, Oberste MS, Monroe SS et al (2003) Characterization of a novel coronavirus associated with severe acute respiratory syndrome. *Science* 300(5624):1394–1399
 57. Marra MA, Jones SJ, Astell CR et al (2003) The genome sequence of the SARS-associated coronavirus. *Science* 300 (5624):1399–1404
 58. Jeffers SA, Tusell SM, Gillim-Ross L et al (2004) CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. *Proc Natl Acad Sci U S A* 20:20
 59. Yang ZY, Kong WP, Huang Y et al (2004) A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. *Nature* 428(6982):561–564
 60. Hogan RJ, Gao G, Rowe T et al (2004) Resolution of primary severe acute respiratory syndrome-associated coronavirus infection requires Stat1. *J Virol* 78(20):11416–11421
 61. Feinberg H, Guo Y, Mitchell DA, Drickamer K, Weis WI (2005) Extended neck regions stabilize tetramers of the receptors DC-SIGN and DC-SIGNR. *J Biol Chem* 280(2):1327–1335
 62. Chan VS, Chan KY, Chen Y et al (2006) Homozygous L-SIGN (CLEC4M) plays a protective role in SARS coronavirus infection. *Nat Genet* 38(1):38–46
 63. Perlman S, Dandekar AA (2005) Immunopathogenesis of coronavirus infections: implications for SARS. *Nat Rev Immunol* 5 (12):917–927
 64. Lau YL, Peiris JS (2005) Pathogenesis of severe acute respiratory syndrome. *Curr Opin Immunol* 17(4):404–410
 65. Li SS, Cheng CW, Fu CL et al (2003) Left ventricular performance in patients with severe acute respiratory syndrome: a 30-day echocardiographic follow-up study. *Circulation* 108 (15):1798–1803
 66. Meldrum DR (1998) Tumor necrosis factor in the heart. *Am J Physiol* 274(3 Pt 2):R577–R595
 67. Wahl SM, Allen JB, Gartner S et al (1989) HIV-1 and its envelope glycoprotein down-regulate chemotactic ligand receptors and chemotactic function of peripheral blood monocytes. *J Immunol* 142(10):3553–3559
 68. Oldstone MB, Lewicki H, Thomas D et al (1999) Measles virus infection in a transgenic model: virus-induced immunosuppression and central nervous system disease. *Cell* 98(5):629–640
 69. Lakadamyali M, Rust MJ, Zhuang X (2004) Endocytosis of influenza viruses. *Microbes Infect* 6(10):929–936
 70. Ungchusak K, Auewarakul P, Dowell SF et al (2005) Probable person-to-person transmission of avian influenza A (H5N1). *N Engl J Med* 352(4):333–340
 71. Geisbert TW, Jahrling PB (2004) Exotic emerging viral diseases: progress and challenges. *Nat Med* 10(Suppl 12):S110–S121
 72. Huentelman MJ, Grobe JL, Vazquez J et al (2005) Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. *Exp Physiol* 90 (5):783–790